<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00354159</url>
  </required_header>
  <id_info>
    <org_study_id>103</org_study_id>
    <nct_id>NCT00354159</nct_id>
  </id_info>
  <brief_title>Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic Heart Failure (HF) (REDUCEhf)</brief_title>
  <acronym>REDUCEhf</acronym>
  <official_title>Reducing Decompensation Events Utilizing Intracardiac Pressures in Patients With Chronic HF (REDUCEhf)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medtronic Cardiac Rhythm and Heart Failure</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medtronic Cardiac Rhythm and Heart Failure</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this clinical research study is to evaluate the safety and effectiveness of
      the investigational implantable hemodynamic monitor (IHM), and of the IHM in combination with
      an implantable cardioverter defibrillator (ICD). The investigational IHM has the ability to
      record and report the force with which the heart pumps blood (heart pressures). When combined
      with the ICD, the device has the additional ability to send a strong electrical impulse, or
      shock, to the heart when it detects dangerously fast heartbeats to return it to a normal
      rhythm. The IHM and IHM/ICD are implanted surgically just under the skin in the upper chest
      area. This study will also determine how doctors use the information related to heart
      pressures in the management of heart failure.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2006</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent of Subjects With an Attempted Implant of the Chronicle ICD System Free From System-related Chronicle ICD Complications at 6-months Post-implant.</measure>
    <time_frame>Within 6 months post-implant</time_frame>
    <description>A Chronicle ICD system-related complication was defined as any system-related adverse event that occurred during the clinical investigation which is (1) treated with invasive means (including intravenous drug therapy), (2) results in death or serious injury of subject, (3) results in the explant of any Chronicle ICD component,and/or (4) causes permanent loss of significant function of the implanted system.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent of Subjects With an Attempted Chronicle IHM Implant Free From Chronicle IHM System-related Complications at 6-months Post-implant</measure>
    <time_frame>6 months post implant</time_frame>
    <description>A Chronicle IHM system-related complication was defined as any system-related adverse event that occurred during the clinical investigation which is (1) treated with invasive means (including intravenous drug therapy), (2) results in death or serious injury of subject, (3) results in the explant of any Chronicle IHM component,and/or (4) causes permanent loss of significant function of the implanted system.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative Risk Reduction of All Heart Failure Related Events in the Treatment Group Compared to the Control Group</measure>
    <time_frame>12 months post-implant</time_frame>
    <description>The rate of HF-related events (hospitalizations &gt;24h, hospitalizations &lt;24h with IV therapy, ED visits with IV therapy, and urgent clinic visits with IV therapy) during the 12-month randomized follow-up period was compared between the Chronicle and Control groups.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cumulative Days in the Hospital for Heart Failure</measure>
    <time_frame>12 months post-implant</time_frame>
    <description>The endpoint for this objective was defined as the cumulative days in hospital for heart failure (HF) expressed as a percentage of hospital free follow-up days during the 12-month randomized period. The relatedness of the events was based on the primary reason for which the subject was originally admitted to the hospital or seen in the emergency department or at an urgent visit, not on the development of new events that occur during hospitalization.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Risk Reduction of Cardiovascular Related Events in the Treatment Group Compared to the Control Group</measure>
    <time_frame>12 months post-implant</time_frame>
    <description>The rate of CV-related events (hospitalizations &gt;24h, hospitalizations &lt;24h with IV therapy, ED visits with IV therapy, and urgent clinic visits with IV therapy) during the 12-month randomized follow-up period was compared between the Chronicle and Control groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Freedom From All Cause Death or Heart Failure Hospitalization</measure>
    <time_frame>12 months post-implant</time_frame>
    <description>Death from any cause or heart failure related hospitalization greater than 24 hours during the 12-month randomized period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative Risk of All-cause Events</measure>
    <time_frame>12 months post-implant</time_frame>
    <description>All-cause events were defined as hospitalizations, hospitalizations &lt;24 hours necessitating intravenous therapy, emergency department visits necessitating intravenous therapy or urgent visits necessitating intravenous therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Randomized Subjects at Each Level of the Composite Response Endpoint Between the Treatment Arm and the Control Arm.</measure>
    <time_frame>12 months post implant</time_frame>
    <description>The definitions of worsened, improved, and unchanged are as follows:
Worsened: Subject dies, is hospitalized for worsening heart failure, permanently discontinues blinded randomized assignment and has worsening heart failure at time of study discontinuation, demonstrates worsening NYHA Class at LOCF, or moderate-marked worsening of global assessment score at LOCF.
Improved: Subject has not worsened, and demonstrates improvement in NYHA class and/or moderate-marked improvement in subject global assessment score.
Unchanged: Subject is neither worsened nor improved.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize Health Resource Utilization</measure>
    <time_frame>12 months post implant</time_frame>
    <description>Percentage of randomized days spent in the intensive care unit for heart failure. Reason for hospitalization was determined by the adverse event adjudication committee.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize Randomized Days Alive Out of Hospital</measure>
    <time_frame>12 months post implant</time_frame>
    <description>Randomized days alive outside of the hospital was computed for each subject as the total number of randomized days minus the number of randomized days spent in the hospital for any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize Subject Survival</measure>
    <time_frame>12 months post implant</time_frame>
    <description>Death from any cause during the 12-month randomization period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize Medication Usage</measure>
    <time_frame>12 months post implant</time_frame>
    <description>The rate of change of cardiovascular medications in changes per subject month were computed and compared between treatment groups.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize Intracardiac Pressure</measure>
    <time_frame>12 months post implant</time_frame>
    <description>The average daily median estimated pulmonary arterial diastolic pressure (ePAD) was computed for each subject with at least 90 days of ePAD data available and compared between the Treatment and Control arms.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize Intracardiac Pressure Changes in Response to Subject Clinical Signs and Symptoms of Heart Failure Events</measure>
    <time_frame>12 months post implant</time_frame>
    <description>The average daily median estimated pulmonary arterial diastolic pressure (ePAD) was computed for each subject with at least 90 days of ePAD data available and compared between the Control Arm subjects with and without a heart failure related event during the 12-month randomized period.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize NYHA Functional Class</measure>
    <time_frame>baseline to 12 months post implant</time_frame>
    <description>The outcome is the change in NYHA functional class between the baseline visit and the 12-month follow-up visit. At baseline subjects were required to be NYHA functional class II or III. The outcome will show the percentage of subjects that were functional class II and III at baseline and functional class I, II, III, or IV at the 12-month visit. The percent improvement from baseline is calculated as the percentage of subjects with a lower NYHA functional class at the 12-month visit compared to their NHYA functional class at baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize Distance Walked in Six Minutes</measure>
    <time_frame>baseline to 12 months post implant</time_frame>
    <description>The outcome is the change in distance walked in 6-minutes in meters between the baseline visit and the 12-month follow-up visit. The change in distance walked was calculated within each subject as the distance walked in 6-minutes at the 12-month visit minus the distance walked in 6-minutes at the baseline visit. Positive values indicate an increase in the distance walked in 6-minutes from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize Renal Function at the Baseline and 12-month Visit</measure>
    <time_frame>baseline to 12 months post implant</time_frame>
    <description>Change in estimated glomerular filtration rate (eGFR) from baseline to the 12-month follow-up visit. eGFR was estimated using the MDRD forumula from the National Kidney Foundation (American Journal of Kidney Diseases 39: S1-299). Change in eGFR was computed as the 12-month eGFR value minus the baseline eGFR value. Positive values indicate an increase in eGFR from baseline and negative values indicate a decrease in eGFR from baseline.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize Intracardiac Pressure Monitoring Following Defibrillation Testing (Chronicle ICD Subjects Only)</measure>
    <time_frame>implant</time_frame>
    <description>Intracardiac pressure monitoring was deemed successful following defibrillation testing if physiological pressure waveforms were present following defibrillation testing.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize Defibrillation Threshold Testing Efficacy (Chronicle ICD Subjects Only)</measure>
    <time_frame>Implant</time_frame>
    <description>The outcome measure is the percentage of subjects implanted with the Chronicle ICD who completed defibrillation testing and had a 10 Joule safety margin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize Quality of Life at Baseline and 12-month Visit</measure>
    <time_frame>baseline to 12 months post implant</time_frame>
    <description>The outcome is the change in the Minnesota Living with Heart Failure® (MNLWHF) questionnaire response from baseline to the 12-month follow-up visit. The MNLWHF questionnaire is a 21 question questionnaire scored from zero (no impact of heart failure) to 5 (severe impact of heart failure). The composite MNLWHF score ranges from 0 (no impact of heart failure) to 105 (severe impact of heart failure). Change in MNLWHF score was computed as the 12-month minus the baseline score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Characterize Arrhythmic Events</measure>
    <time_frame>12 months post implant</time_frame>
    <description>The rate of spontaneous VT (ventricular tachycardia)/VF (ventricular fibrillation) episodes during the 12-month follow-up period in episodes per subject month was compared between the Treatment Arm and the Control Arm</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">442</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Physicians do not have access to device-based hemodynamic monitor information to guide patient management</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implantable Hemodynamic Monitor (Chronicle® IHM), and IHM in combination with single chamber ICD (Chronicle ICD)</intervention_name>
    <description>Surgical implantation of hemodynamic device (IHM), or IHM/ICD, and intracardiac leads.</description>
    <arm_group_label>Treatment Arm</arm_group_label>
    <arm_group_label>Control Arm</arm_group_label>
    <other_name>Chronicle® IHM, Chronicle® ICD</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects with heart failure that only sometimes interferes with daily activities (New
             York Heart Association [NYHA] Class II (1)) or subjects with heart failure which
             severely limits daily activities (NYHA Class III (2)) at baseline

          -  Subject has appropriate medical therapy for heart failure (such as diuretic,
             angiotensin-converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB)
             and beta blocker) for at least three months prior to the baseline evaluation.

          -  Subject has been on stable medications maximized to the subject's tolerance of ACE or
             ARB and beta blockers as determined by the study investigator for at least 30 days
             prior to baseline evaluation. (Stable is defined as no more than a 100% increase or a
             50% decrease in dose.) If a subject is intolerant of ACE, ARB or beta blockers
             documented evidence must be available.

          -  Subject has had at least one heart failure-related hospitalization or at least one
             heart failure-related emergency department or urgent care visit necessitating heart
             failure-related intravenous therapy (e.g. diuretic administration) within 12 months
             prior to the baseline evaluation

          -  To be considered for Chronicle ICD: Subject has, or is at risk of having, a heart beat
             that is too fast and his/her doctor has determined he/she needs an implantable
             cardioverter defibrillator (ICD).

               1. Class II Subjects with cardiac disease resulting in slight limitation of physical
                  activity. They are comfortable at rest. Ordinary physical activity results in
                  fatigue, palpitation, dyspnea, or angina.

               2. Class III Subjects with cardiac disease resulting in marked limitation of
                  physical activity. They are comfortable at rest. Less than ordinary activity
                  causes fatigue, palpitation, dyspnea, or angina.

        Exclusion Criteria:

          -  Subjects with severe heart failure who should always be resting (NYHA Class IV(3)) or
             Stage D(4) refractory heart failure.

          -  Subjects with severe renal dysfunction.

          -  Subjects with severe non-cardiac condition limiting 12-month survival.

          -  Subjects in concurrent studies that may confound the results.

             (3)Class IV Subjects with cardiac disease resulting in inability to carry on any
             physical activity without discomfort. Symptoms of heart failure or the anginal
             syndrome may be present even at rest. If any physical activity is undertaken,
             discomfort is increased.

             (4)Stage D refractory heart failure: Patients who have marked symptoms at rest despite
             maximal medical therapy (e.g., those who are recurrently hospitalized or cannot be
             safely discharged from the hospital without specialized interventions)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phillip Adamson, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Oklahoma Heart Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Michael Gold, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Medical University of South Carolina</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Alabama at Birmingham (UAB)</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Scripps Green Hospital</name>
      <address>
        <city>LaJolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cedars-Sinai Medical Center</name>
      <address>
        <city>LA</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Loma Linda University Medical Center</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92354</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Long Beach Memorial</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Doctors Medical Center Modesto</name>
      <address>
        <city>Modesto</city>
        <state>California</state>
        <zip>95350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yale University, School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christiana Care Hospital</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19718</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of FL Shands</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32610</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Crawford Long/Emory University Hospitals</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30308</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Heart Foundation</name>
      <address>
        <city>Lombard</city>
        <state>Illinois</state>
        <zip>60148</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Genesis Hospital Midwest Cardiovascular Research Foundation</name>
      <address>
        <city>Davenport</city>
        <state>Iowa</state>
        <zip>52803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iowa Heart Center</name>
      <address>
        <city>West Des Moines</city>
        <state>Iowa</state>
        <zip>50266</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brigham &amp; Women's Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lahey Clinic Medical Center</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01805</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Massachusetts Memorial Medical Center</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01655</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Joseph Mercy Hospital</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Hospital</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mercy Hospital Metropolitan Cardiology Consultants</name>
      <address>
        <city>Coon Rapids</city>
        <state>Minnesota</state>
        <zip>55433</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Mississippi Medical Center</name>
      <address>
        <city>Tupelo</city>
        <state>Mississippi</state>
        <zip>38801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mid America Heart Institute/St. Lukes</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bryan LGH Heart Institute</name>
      <address>
        <city>Lincoln</city>
        <state>Nebraska</state>
        <zip>68506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Morristown Memorial Hospital</name>
      <address>
        <city>Morristown</city>
        <state>New Jersey</state>
        <zip>07962</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mt Sinai Medical Center</name>
      <address>
        <city>New York City</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolinas Medical Center</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presbyterian Hospital Mid Carolinas Cardiology</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Forsyth Medical Center</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>27103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christ Hospital</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ohio State University</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Oklahoma</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oklahoma Heart Hospital</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73120</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Heart Specialists</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lancaster Heart &amp; Stroke Foundation</name>
      <address>
        <city>Lancaster</city>
        <state>Pennsylvania</state>
        <zip>17603</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Drexel University College of Medicine</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19102</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital of the University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Allegheny General Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15212</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lankenau Hospital</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Spartanburg Regional</name>
      <address>
        <city>Spartanburg</city>
        <state>South Carolina</state>
        <zip>29303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baptist Hospital</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Thomas</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37205</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Baylor Research Institute</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75226</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fletcher Allen Health Care</name>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <zip>05401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia Health System</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inova Fairfax Hospital</name>
      <address>
        <city>Falls Church</city>
        <state>Virginia</state>
        <zip>22042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sentara Norfolk General Hospital</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23507</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin Hospital &amp; Clinics</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53792</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Canada</country>
  </removed_countries>
  <verification_date>August 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 19, 2006</study_first_submitted>
  <study_first_submitted_qc>July 19, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2006</study_first_posted>
  <results_first_submitted>January 12, 2012</results_first_submitted>
  <results_first_submitted_qc>August 7, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">August 9, 2012</results_first_posted>
  <last_update_submitted>August 7, 2012</last_update_submitted>
  <last_update_submitted_qc>August 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 9, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Implantable cardioverter defibrillator</keyword>
  <keyword>Intracardiac pressures</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Recruitment began on April 28, 2006 and ended on January 14, 2011. All subjects were exited from the study on January 14, 2011. Fifty-three US clinical centers participated in the REDUCEhf study.</recruitment_details>
      <pre_assignment_details>Enrolled subjects were required to have a successful implant of the Chronicle® device prior to randomization. 407 subjects had an attempted implant of the Chronicle® ICD (Implantable Cardioverter Defibrillator) (406) or Chronicle IHM (Implantable Hemodynamic Monitor) (1 subject). Of these 407 subjects, 400 were randomized.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment Arm</title>
          <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
        </group>
        <group group_id="P2">
          <title>Control Arm</title>
          <description>Physicians do not have access to device-based hemodynamic monitor information to guide patient management</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Randomized Study Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="202"/>
                <participants group_id="P2" count="198"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="180"/>
                <participants group_id="P2" count="176"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="22"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Long-term Follow-up</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="180">Number entering post 12-month non-randomized long-term follow-up period</participants>
                <participants group_id="P2" count="176">Number entering post 12-month non-randomized long-term follow-up period</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0">All subjects were exited at the time of study closure</participants>
                <participants group_id="P2" count="0">All subjects were exited at the time of study closure</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="180"/>
                <participants group_id="P2" count="176"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="127"/>
                <participants group_id="P2" count="122"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Death</title>
              <participants_list>
                <participants group_id="P1" count="14"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Closed</title>
              <participants_list>
                <participants group_id="P1" count="29"/>
                <participants group_id="P2" count="34"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Treatment Arm</title>
          <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
        </group>
        <group group_id="B2">
          <title>Control Arm</title>
          <description>Physicians do not have access to device-based hemodynamic monitor information to guide patient management</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="202"/>
            <count group_id="B2" value="198"/>
            <count group_id="B3" value="400"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="151"/>
                    <measurement group_id="B2" value="144"/>
                    <measurement group_id="B3" value="295"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="54"/>
                    <measurement group_id="B3" value="105"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54.8" spread="14.7"/>
                    <measurement group_id="B2" value="54.7" spread="14.8"/>
                    <measurement group_id="B3" value="54.7" spread="14.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="126"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="141"/>
                    <measurement group_id="B2" value="133"/>
                    <measurement group_id="B3" value="274"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="202"/>
                    <measurement group_id="B2" value="198"/>
                    <measurement group_id="B3" value="400"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>NYHA (New York Heart Association) Classification</title>
          <description>Class II and Class III NYHA classification
Class II Subjects with cardiac disease resulting in slight limitation of physical activity.They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or angina.
Class III Subjects with cardiac disease resulting in marked limitation of physical activity.They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or angina.</description>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>NYHA Class II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="107"/>
                    <measurement group_id="B2" value="90"/>
                    <measurement group_id="B3" value="197"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NYHA Class III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="95"/>
                    <measurement group_id="B2" value="108"/>
                    <measurement group_id="B3" value="203"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent of Subjects With an Attempted Implant of the Chronicle ICD System Free From System-related Chronicle ICD Complications at 6-months Post-implant.</title>
        <description>A Chronicle ICD system-related complication was defined as any system-related adverse event that occurred during the clinical investigation which is (1) treated with invasive means (including intravenous drug therapy), (2) results in death or serious injury of subject, (3) results in the explant of any Chronicle ICD component,and/or (4) causes permanent loss of significant function of the implanted system.</description>
        <time_frame>Within 6 months post-implant</time_frame>
        <population>All 406 subjects with an attempted implant of the Chronicle ICD system.</population>
        <group_list>
          <group group_id="O1">
            <title>Chronicle ICD Implanted Subjects</title>
            <description>Analysis cohort includes all 406 subjects with an attempted implant of the Chronicle ICD system.</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects With an Attempted Implant of the Chronicle ICD System Free From System-related Chronicle ICD Complications at 6-months Post-implant.</title>
          <description>A Chronicle ICD system-related complication was defined as any system-related adverse event that occurred during the clinical investigation which is (1) treated with invasive means (including intravenous drug therapy), (2) results in death or serious injury of subject, (3) results in the explant of any Chronicle ICD component,and/or (4) causes permanent loss of significant function of the implanted system.</description>
          <population>All 406 subjects with an attempted implant of the Chronicle ICD system.</population>
          <units>Percentage of Chronicle ICD Subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="406"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.5" lower_limit="87.7" upper_limit="93.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: Freedom from Chronicle system-related complications at 6-months post-implant is less than or equal to 80%.
Alternative hypothesis: Freedom from Chronicle system-related complications at 6-months is greater than 80%.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.001</p_value>
            <p_value_desc>The survival estimate at 6-months post-implant was compared to 80%. The comparison was made using the cumulative hazard [e.g. log survival estimate] for the variance.</p_value_desc>
            <method>Survival estimate at 6-months</method>
            <method_desc>The survival estimate at 6-months post-implant was compared to 80%.</method_desc>
            <param_type>6-month survival rate</param_type>
            <param_value>90.5</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>1-Sided</ci_n_sides>
            <ci_lower_limit>87.7</ci_lower_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percent of Subjects With an Attempted Chronicle IHM Implant Free From Chronicle IHM System-related Complications at 6-months Post-implant</title>
        <description>A Chronicle IHM system-related complication was defined as any system-related adverse event that occurred during the clinical investigation which is (1) treated with invasive means (including intravenous drug therapy), (2) results in death or serious injury of subject, (3) results in the explant of any Chronicle IHM component,and/or (4) causes permanent loss of significant function of the implanted system.</description>
        <time_frame>6 months post implant</time_frame>
        <population>All subjects with an attempted implant of the Chronicle IHM system were included in this analysis. At the time the study stopped, there was only one subject with an attempted Chronicle IHM implant. Thus this objective was not analyzed.</population>
        <group_list>
          <group group_id="O1">
            <title>Chronicle IHM Implanted Subjects</title>
            <description>Analysis cohort includes the one subject with a Chronicle IHM implant attempt</description>
          </group>
        </group_list>
        <measure>
          <title>Percent of Subjects With an Attempted Chronicle IHM Implant Free From Chronicle IHM System-related Complications at 6-months Post-implant</title>
          <description>A Chronicle IHM system-related complication was defined as any system-related adverse event that occurred during the clinical investigation which is (1) treated with invasive means (including intravenous drug therapy), (2) results in death or serious injury of subject, (3) results in the explant of any Chronicle IHM component,and/or (4) causes permanent loss of significant function of the implanted system.</description>
          <population>All subjects with an attempted implant of the Chronicle IHM system were included in this analysis. At the time the study stopped, there was only one subject with an attempted Chronicle IHM implant. Thus this objective was not analyzed.</population>
          <units>Percent of Chronicle IHM subjects</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100" lower_limit="100" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Relative Risk Reduction of All Heart Failure Related Events in the Treatment Group Compared to the Control Group</title>
        <description>The rate of HF-related events (hospitalizations &gt;24h, hospitalizations &lt;24h with IV therapy, ED visits with IV therapy, and urgent clinic visits with IV therapy) during the 12-month randomized follow-up period was compared between the Chronicle and Control groups.</description>
        <time_frame>12 months post-implant</time_frame>
        <population>All randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Physicians do not have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Risk Reduction of All Heart Failure Related Events in the Treatment Group Compared to the Control Group</title>
          <description>The rate of HF-related events (hospitalizations &gt;24h, hospitalizations &lt;24h with IV therapy, ED visits with IV therapy, and urgent clinic visits with IV therapy) during the 12-month randomized follow-up period was compared between the Chronicle and Control groups.</description>
          <population>All randomized subjects</population>
          <units>Heart failure related events per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.48" lower_limit="0.38" upper_limit="0.58"/>
                    <measurement group_id="O2" value="0.49" lower_limit="0.39" upper_limit="0.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The study was originally powered at 80% to detect a 25% risk reduction between the treatment arm and control arm with a type I error rate of 0.05. Under these assumptions 648 HF-related events from approximately 1300 subjects were required. The study stopped after 400 were randomized.
Null Hypothesis: The HF-related event rate is the same between the treatment arm and control arm.
Alternative Hypothesis: The HF-related event rate between the treatment arm and control arm is different.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.978</p_value>
            <p_value_desc>The P-value is from the Andersen-Gill model, an extension of the Cox proportional hazards model for multiple events.</p_value_desc>
            <method>Andersen-Gill</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.99</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.61</ci_lower_limit>
            <ci_upper_limit>1.61</ci_upper_limit>
            <estimate_desc>Hazard Ratio is for the Treatment Arm relative to the Control Arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Cumulative Days in the Hospital for Heart Failure</title>
        <description>The endpoint for this objective was defined as the cumulative days in hospital for heart failure (HF) expressed as a percentage of hospital free follow-up days during the 12-month randomized period. The relatedness of the events was based on the primary reason for which the subject was originally admitted to the hospital or seen in the emergency department or at an urgent visit, not on the development of new events that occur during hospitalization.</description>
        <time_frame>12 months post-implant</time_frame>
        <population>All follow-up from all randomized subjects were included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Physicians do NOT have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
        </group_list>
        <measure>
          <title>Cumulative Days in the Hospital for Heart Failure</title>
          <description>The endpoint for this objective was defined as the cumulative days in hospital for heart failure (HF) expressed as a percentage of hospital free follow-up days during the 12-month randomized period. The relatedness of the events was based on the primary reason for which the subject was originally admitted to the hospital or seen in the emergency department or at an urgent visit, not on the development of new events that occur during hospitalization.</description>
          <population>All follow-up from all randomized subjects were included in this analysis.</population>
          <units>Percent days in hospital</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="0" upper_limit="22"/>
                    <measurement group_id="O2" value="0" lower_limit="0" upper_limit="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: mu(Treatment) = mu(Control) Alternative Hypothesis: mu(Treatment) ne mu(Control)
where mu is the percentage of hospitalized days for heart failure.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.574</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Risk Reduction of Cardiovascular Related Events in the Treatment Group Compared to the Control Group</title>
        <description>The rate of CV-related events (hospitalizations &gt;24h, hospitalizations &lt;24h with IV therapy, ED visits with IV therapy, and urgent clinic visits with IV therapy) during the 12-month randomized follow-up period was compared between the Chronicle and Control groups.</description>
        <time_frame>12 months post-implant</time_frame>
        <population>All randomized follow-up for all randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Physicians do NOT have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Risk Reduction of Cardiovascular Related Events in the Treatment Group Compared to the Control Group</title>
          <description>The rate of CV-related events (hospitalizations &gt;24h, hospitalizations &lt;24h with IV therapy, ED visits with IV therapy, and urgent clinic visits with IV therapy) during the 12-month randomized follow-up period was compared between the Chronicle and Control groups.</description>
          <population>All randomized follow-up for all randomized subjects.</population>
          <units>Cardiovascular related events per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.77" lower_limit="0.64" upper_limit="0.89"/>
                    <measurement group_id="O2" value="0.86" lower_limit="0.71" upper_limit="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: The CV-related event rate is the same between the treatment arm and control arm.
Alternative Hypothesis: The CV-related event rate between the treatment arm and control arm is different.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.527</p_value>
            <p_value_desc>The P-value is from the Andersen-Gill model, an extension of the Cox proportional hazards model for multiple events.</p_value_desc>
            <method>Andersen-Gill Model</method>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.89</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.62</ci_lower_limit>
            <ci_upper_limit>1.28</ci_upper_limit>
            <estimate_desc>Hazard Ratio is for the Treatment Arm relative to the Control Arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Freedom From All Cause Death or Heart Failure Hospitalization</title>
        <description>Death from any cause or heart failure related hospitalization greater than 24 hours during the 12-month randomized period</description>
        <time_frame>12 months post-implant</time_frame>
        <population>All randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Physicians do NOT have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
        </group_list>
        <measure>
          <title>Freedom From All Cause Death or Heart Failure Hospitalization</title>
          <description>Death from any cause or heart failure related hospitalization greater than 24 hours during the 12-month randomized period</description>
          <population>All randomized subjects</population>
          <units>Number of subjects meeting endpoint</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="42" lower_limit="0.73" upper_limit="0.85"/>
                    <measurement group_id="O2" value="47" lower_limit="0.70" upper_limit="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Freedom from death or HF-related hospitalization is the same between the treatment arm and the control arm.
Alternative Hypothesis: Freedom from death or HF-related hospitalization is different between the treatment arm and the control arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.505</p_value>
            <method>Regression, Cox</method>
            <method_desc>The treatment and control hazard ratio and 95% confidence interval was estimated using a univariate cox Regression Model.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.87</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.57</ci_lower_limit>
            <ci_upper_limit>1.32</ci_upper_limit>
            <estimate_desc>Hazard Ratio is for the Treatment Arm relative to the Control Arm</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Relative Risk of All-cause Events</title>
        <description>All-cause events were defined as hospitalizations, hospitalizations &lt;24 hours necessitating intravenous therapy, emergency department visits necessitating intravenous therapy or urgent visits necessitating intravenous therapy.</description>
        <time_frame>12 months post-implant</time_frame>
        <population>All randomized follow-up from all randomized subjects</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Physicians do NOT have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Risk of All-cause Events</title>
          <description>All-cause events were defined as hospitalizations, hospitalizations &lt;24 hours necessitating intravenous therapy, emergency department visits necessitating intravenous therapy or urgent visits necessitating intravenous therapy.</description>
          <population>All randomized follow-up from all randomized subjects</population>
          <units>All cause event rate per year</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.18" lower_limit="1.03" upper_limit="1.34"/>
                    <measurement group_id="O2" value="1.55" lower_limit="1.36" upper_limit="1.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: The all cause event rate is the same between the treatment arm and control arm.
Alternative Hypothesis: The all cause event rate between the treatment arm and control arm is different.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.088</p_value>
            <method>Andersen-Gill Model</method>
            <method_desc>The P-value is from the Andersen-Gill model, an extension of the Cox proportional hazards model for multiple events.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.76</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.56</ci_lower_limit>
            <ci_upper_limit>1.04</ci_upper_limit>
            <estimate_desc>Hazard Ratio is for the Treatment Arm relative to the Control Arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Randomized Subjects at Each Level of the Composite Response Endpoint Between the Treatment Arm and the Control Arm.</title>
        <description>The definitions of worsened, improved, and unchanged are as follows:
Worsened: Subject dies, is hospitalized for worsening heart failure, permanently discontinues blinded randomized assignment and has worsening heart failure at time of study discontinuation, demonstrates worsening NYHA Class at LOCF, or moderate-marked worsening of global assessment score at LOCF.
Improved: Subject has not worsened, and demonstrates improvement in NYHA class and/or moderate-marked improvement in subject global assessment score.
Unchanged: Subject is neither worsened nor improved.</description>
        <time_frame>12 months post implant</time_frame>
        <population>All randomized follow-up from all randomized subjects were included.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Physicians do NOT have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Randomized Subjects at Each Level of the Composite Response Endpoint Between the Treatment Arm and the Control Arm.</title>
          <description>The definitions of worsened, improved, and unchanged are as follows:
Worsened: Subject dies, is hospitalized for worsening heart failure, permanently discontinues blinded randomized assignment and has worsening heart failure at time of study discontinuation, demonstrates worsening NYHA Class at LOCF, or moderate-marked worsening of global assessment score at LOCF.
Improved: Subject has not worsened, and demonstrates improvement in NYHA class and/or moderate-marked improvement in subject global assessment score.
Unchanged: Subject is neither worsened nor improved.</description>
          <population>All randomized follow-up from all randomized subjects were included.</population>
          <units>Percent of Subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Subjects Improved</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51"/>
                    <measurement group_id="O2" value="51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Subjects Unchanged</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Subjects Worsened</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Distribution of composite response endpoint is the same between the treatment arm and the control arm.
Alternative Hypothesis: Distribution of composite response endpoint is different between the treatment arm and the control arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.758</p_value>
            <p_value_desc>P-value is from a proportional odds model comparing the distribution of composite endpoint response between the treatment arm and control arm.</p_value_desc>
            <method>Proportional odds model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.73</ci_lower_limit>
            <ci_upper_limit>1.54</ci_upper_limit>
            <estimate_desc>Odds ratio represents the odds of improved score in the treatment group relative to the control group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterize Health Resource Utilization</title>
        <description>Percentage of randomized days spent in the intensive care unit for heart failure. Reason for hospitalization was determined by the adverse event adjudication committee.</description>
        <time_frame>12 months post implant</time_frame>
        <population>All randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Physicians do not have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
        </group_list>
        <measure>
          <title>Characterize Health Resource Utilization</title>
          <description>Percentage of randomized days spent in the intensive care unit for heart failure. Reason for hospitalization was determined by the adverse event adjudication committee.</description>
          <population>All randomized subjects.</population>
          <units>percentage of randomized days</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.1" lower_limit="0" upper_limit="5.3"/>
                    <measurement group_id="O2" value="0.4" lower_limit="0" upper_limit="35.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterize Randomized Days Alive Out of Hospital</title>
        <description>Randomized days alive outside of the hospital was computed for each subject as the total number of randomized days minus the number of randomized days spent in the hospital for any cause.</description>
        <time_frame>12 months post implant</time_frame>
        <population>All randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Physicians do not have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
        </group_list>
        <measure>
          <title>Characterize Randomized Days Alive Out of Hospital</title>
          <description>Randomized days alive outside of the hospital was computed for each subject as the total number of randomized days minus the number of randomized days spent in the hospital for any cause.</description>
          <population>All randomized subjects.</population>
          <units>Days</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="340" spread="65"/>
                    <measurement group_id="O2" value="341" spread="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterize Subject Survival</title>
        <description>Death from any cause during the 12-month randomization period</description>
        <time_frame>12 months post implant</time_frame>
        <population>All randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Physicians do not have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
        </group_list>
        <measure>
          <title>Characterize Subject Survival</title>
          <description>Death from any cause during the 12-month randomization period</description>
          <population>All randomized subjects.</population>
          <units>number of deaths</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: Survival during the 12-month randomized follow-up period is the same between the treatment and control groups.
Alternative hypothesis: Survival during the 12-month randomized period is different between the treatment and control groups.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.599</p_value>
            <method>Regression, Cox</method>
            <method_desc>The treatment to control hazard ratio and 95% confidence interval was estimated using a univariate Cox Regression Model</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>0.77</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.29</ci_lower_limit>
            <ci_upper_limit>2.06</ci_upper_limit>
            <estimate_desc>Hazard ratio estimates the hazard of death in the treatment group relative to the control group.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterize Medication Usage</title>
        <description>The rate of change of cardiovascular medications in changes per subject month were computed and compared between treatment groups.</description>
        <time_frame>12 months post implant</time_frame>
        <population>All randomized subjects.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Physicians do not have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
        </group_list>
        <measure>
          <title>Characterize Medication Usage</title>
          <description>The rate of change of cardiovascular medications in changes per subject month were computed and compared between treatment groups.</description>
          <population>All randomized subjects.</population>
          <units>Medication changes per subject month</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="198"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.77"/>
                    <measurement group_id="O2" value="1.49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The null hypothesis is that the rate of cardiovascular medication changes is the same between the Treatment Arm and Control Arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.145</p_value>
            <method>Negative-Binomial Regression</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterize Intracardiac Pressure</title>
        <description>The average daily median estimated pulmonary arterial diastolic pressure (ePAD) was computed for each subject with at least 90 days of ePAD data available and compared between the Treatment and Control arms.</description>
        <time_frame>12 months post implant</time_frame>
        <population>At least 90 days of ePAD data were required for each subject during the 12-month randomized period to be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Physicians do not have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
        </group_list>
        <measure>
          <title>Characterize Intracardiac Pressure</title>
          <description>The average daily median estimated pulmonary arterial diastolic pressure (ePAD) was computed for each subject with at least 90 days of ePAD data available and compared between the Treatment and Control arms.</description>
          <population>At least 90 days of ePAD data were required for each subject during the 12-month randomized period to be included in the analysis.</population>
          <units>ePAD mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="191"/>
                <count group_id="O2" value="181"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.0" spread="5.6"/>
                    <measurement group_id="O2" value="23.3" spread="6.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis: Average daily median ePAD is the same between the Treatment and Control arms.
Alternative hypothesis: Average daily median ePAD is the different between the Treatment and Control arms.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.033</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterize Intracardiac Pressure Changes in Response to Subject Clinical Signs and Symptoms of Heart Failure Events</title>
        <description>The average daily median estimated pulmonary arterial diastolic pressure (ePAD) was computed for each subject with at least 90 days of ePAD data available and compared between the Control Arm subjects with and without a heart failure related event during the 12-month randomized period.</description>
        <time_frame>12 months post implant</time_frame>
        <population>All Control Arm subjects with at least 90 days of pressure data available during the 12-month randomized follow-up period.</population>
        <group_list>
          <group group_id="O1">
            <title>Heart Failure Event Free Control Subjects</title>
            <description>Subjects randomized to the Control Arm that did not have a heart failure related event during the 12-month randomized period</description>
          </group>
          <group group_id="O2">
            <title>Heart Failure Event Control Subjects</title>
            <description>Subjects randomized to the Control Arm that had a heart failure event during the 12-month randomized period</description>
          </group>
        </group_list>
        <measure>
          <title>Characterize Intracardiac Pressure Changes in Response to Subject Clinical Signs and Symptoms of Heart Failure Events</title>
          <description>The average daily median estimated pulmonary arterial diastolic pressure (ePAD) was computed for each subject with at least 90 days of ePAD data available and compared between the Control Arm subjects with and without a heart failure related event during the 12-month randomized period.</description>
          <population>All Control Arm subjects with at least 90 days of pressure data available during the 12-month randomized follow-up period.</population>
          <units>ePAD mm Hg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="143"/>
                <count group_id="O2" value="38"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26.3" spread="6.5"/>
                    <measurement group_id="O2" value="22.5" spread="6.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: The average daily median ePAD is not different among Control Arm subjects that have and that do not have a heart failure related event during the 12-month follow-up period.
Alternative Hypothesis: The average daily median ePAD is different among Control Arm subjects that have and that do not have a heart failure related event during the 12-month follow-up period.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.002</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterize NYHA Functional Class</title>
        <description>The outcome is the change in NYHA functional class between the baseline visit and the 12-month follow-up visit. At baseline subjects were required to be NYHA functional class II or III. The outcome will show the percentage of subjects that were functional class II and III at baseline and functional class I, II, III, or IV at the 12-month visit. The percent improvement from baseline is calculated as the percentage of subjects with a lower NYHA functional class at the 12-month visit compared to their NHYA functional class at baseline.</description>
        <time_frame>baseline to 12 months post implant</time_frame>
        <population>Subjects were required to have an NYHA functional class assessment at the baseline and 12-month follow-up visit to be included in this analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Physicians do not have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
        </group_list>
        <measure>
          <title>Characterize NYHA Functional Class</title>
          <description>The outcome is the change in NYHA functional class between the baseline visit and the 12-month follow-up visit. At baseline subjects were required to be NYHA functional class II or III. The outcome will show the percentage of subjects that were functional class II and III at baseline and functional class I, II, III, or IV at the 12-month visit. The percent improvement from baseline is calculated as the percentage of subjects with a lower NYHA functional class at the 12-month visit compared to their NHYA functional class at baseline.</description>
          <population>Subjects were required to have an NYHA functional class assessment at the baseline and 12-month follow-up visit to be included in this analysis.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Percent Subjects NYHA Class II Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55" lower_limit="36" upper_limit="51"/>
                    <measurement group_id="O2" value="48" lower_limit="33" upper_limit="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Subjects NYHA Class III Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Subjects NYHA Class I Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24"/>
                    <measurement group_id="O2" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Subjects NYHA Class II Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="46"/>
                    <measurement group_id="O2" value="52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Subjects NYHA Class III Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Subjects NYHA Class IV Month 12</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Subjects Improved NYHA Class</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="44"/>
                    <measurement group_id="O2" value="41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Subjects No Change in NYHA Class</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Percent Subjects Worsened NYHA Class</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12"/>
                    <measurement group_id="O2" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: There is no difference in the change in NYHA functional class between the Treatment and Control Arms.
Alternative Hypothesis: There is a difference in the change in NYHA functional class between the Treatment and Control Arms.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.292</p_value>
            <method>Proportional odds regression model</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.82</ci_lower_limit>
            <ci_upper_limit>1.96</ci_upper_limit>
            <estimate_desc>Direction for odds ratio is the odds of improvement in the Treatment arm versus the odds of improvement in the Control arm.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterize Distance Walked in Six Minutes</title>
        <description>The outcome is the change in distance walked in 6-minutes in meters between the baseline visit and the 12-month follow-up visit. The change in distance walked was calculated within each subject as the distance walked in 6-minutes at the 12-month visit minus the distance walked in 6-minutes at the baseline visit. Positive values indicate an increase in the distance walked in 6-minutes from baseline.</description>
        <time_frame>baseline to 12 months post implant</time_frame>
        <population>Subjects were required to complete the 6-minute hall walk test at both the baseline and 12-month visit to be included in the analysis of this objective.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Physicians do not have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
        </group_list>
        <measure>
          <title>Characterize Distance Walked in Six Minutes</title>
          <description>The outcome is the change in distance walked in 6-minutes in meters between the baseline visit and the 12-month follow-up visit. The change in distance walked was calculated within each subject as the distance walked in 6-minutes at the 12-month visit minus the distance walked in 6-minutes at the baseline visit. Positive values indicate an increase in the distance walked in 6-minutes from baseline.</description>
          <population>Subjects were required to complete the 6-minute hall walk test at both the baseline and 12-month visit to be included in the analysis of this objective.</population>
          <units>distance walked in 6-minutes (meters)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="157"/>
                <count group_id="O2" value="153"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="313.2" spread="124.8"/>
                    <measurement group_id="O2" value="308.7" spread="133.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-month visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="354.5" spread="178.8"/>
                    <measurement group_id="O2" value="347.2" spread="160.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from baseline to 12-months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.3" spread="160.5"/>
                    <measurement group_id="O2" value="38.5" spread="154.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: The change in 6-minute hall walk distance is not different between the Treatment and Control Arms.
Alternative Hypothesis: The change in 6-minute hall walk distance is different between the Treatment and Control Arms.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.996</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterize Renal Function at the Baseline and 12-month Visit</title>
        <description>Change in estimated glomerular filtration rate (eGFR) from baseline to the 12-month follow-up visit. eGFR was estimated using the MDRD forumula from the National Kidney Foundation (American Journal of Kidney Diseases 39: S1-299). Change in eGFR was computed as the 12-month eGFR value minus the baseline eGFR value. Positive values indicate an increase in eGFR from baseline and negative values indicate a decrease in eGFR from baseline.</description>
        <time_frame>baseline to 12 months post implant</time_frame>
        <population>Subjects were required to have creatinine values available at the baseline and 12-month visit to be included in the analysis of this objective.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Physicians do not have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
        </group_list>
        <measure>
          <title>Characterize Renal Function at the Baseline and 12-month Visit</title>
          <description>Change in estimated glomerular filtration rate (eGFR) from baseline to the 12-month follow-up visit. eGFR was estimated using the MDRD forumula from the National Kidney Foundation (American Journal of Kidney Diseases 39: S1-299). Change in eGFR was computed as the 12-month eGFR value minus the baseline eGFR value. Positive values indicate an increase in eGFR from baseline and negative values indicate a decrease in eGFR from baseline.</description>
          <population>Subjects were required to have creatinine values available at the baseline and 12-month visit to be included in the analysis of this objective.</population>
          <units>mL/min/1.73 m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="175"/>
                <count group_id="O2" value="173"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline eGFR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.4" spread="26.2"/>
                    <measurement group_id="O2" value="69.8" spread="20.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-month eGFR</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.6" spread="27.7"/>
                    <measurement group_id="O2" value="69.2" spread="25.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in eGFR from baseline to 12-months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.8" spread="22.0"/>
                    <measurement group_id="O2" value="-0.6" spread="19.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: The change from baseline to the 12-month follow-up visit in eGFR values is the same between the Treatment arm and Control arm.
Alternative Hypothesis: The change from baseline to the 12-month follow-up visit in eGFR values is different between the Treatment arm and Control arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.154</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterize Intracardiac Pressure Monitoring Following Defibrillation Testing (Chronicle ICD Subjects Only)</title>
        <description>Intracardiac pressure monitoring was deemed successful following defibrillation testing if physiological pressure waveforms were present following defibrillation testing.</description>
        <time_frame>implant</time_frame>
        <population>Of the 406 subjects with an attempted implant of the Chronicle ICD system, 366 completed defibrillation testing as part of their ICD implant procedure.</population>
        <group_list>
          <group group_id="O1">
            <title>Chronicle ICD Implanted Subjects</title>
            <description>Analysis cohort includes all 406 subjects with an attempted implant of the Chronicle ICD system</description>
          </group>
        </group_list>
        <measure>
          <title>Characterize Intracardiac Pressure Monitoring Following Defibrillation Testing (Chronicle ICD Subjects Only)</title>
          <description>Intracardiac pressure monitoring was deemed successful following defibrillation testing if physiological pressure waveforms were present following defibrillation testing.</description>
          <population>Of the 406 subjects with an attempted implant of the Chronicle ICD system, 366 completed defibrillation testing as part of their ICD implant procedure.</population>
          <units>Percentage of subjects with waveforms</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.7" lower_limit="98.5" upper_limit="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterize Defibrillation Threshold Testing Efficacy (Chronicle ICD Subjects Only)</title>
        <description>The outcome measure is the percentage of subjects implanted with the Chronicle ICD who completed defibrillation testing and had a 10 Joule safety margin</description>
        <time_frame>Implant</time_frame>
        <population>Of the 406 subjects with an attempted implant of the Chronicle ICD system, 366 completed defibrillation testing.</population>
        <group_list>
          <group group_id="O1">
            <title>Chronicle ICD Implanted Subjects</title>
            <description>Analysis cohort includes all 406 subjects with an attempted implant of the Chronicle ICD system</description>
          </group>
        </group_list>
        <measure>
          <title>Characterize Defibrillation Threshold Testing Efficacy (Chronicle ICD Subjects Only)</title>
          <description>The outcome measure is the percentage of subjects implanted with the Chronicle ICD who completed defibrillation testing and had a 10 Joule safety margin</description>
          <population>Of the 406 subjects with an attempted implant of the Chronicle ICD system, 366 completed defibrillation testing.</population>
          <units>percentage of subjects</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="366"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="98.9" lower_limit="97.2" upper_limit="99.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterize Quality of Life at Baseline and 12-month Visit</title>
        <description>The outcome is the change in the Minnesota Living with Heart Failure® (MNLWHF) questionnaire response from baseline to the 12-month follow-up visit. The MNLWHF questionnaire is a 21 question questionnaire scored from zero (no impact of heart failure) to 5 (severe impact of heart failure). The composite MNLWHF score ranges from 0 (no impact of heart failure) to 105 (severe impact of heart failure). Change in MNLWHF score was computed as the 12-month minus the baseline score.</description>
        <time_frame>baseline to 12 months post implant</time_frame>
        <population>Subjects were required to respond to the baseline and 12-month follow-up visit to be included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Physicians do not have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
        </group_list>
        <measure>
          <title>Characterize Quality of Life at Baseline and 12-month Visit</title>
          <description>The outcome is the change in the Minnesota Living with Heart Failure® (MNLWHF) questionnaire response from baseline to the 12-month follow-up visit. The MNLWHF questionnaire is a 21 question questionnaire scored from zero (no impact of heart failure) to 5 (severe impact of heart failure). The composite MNLWHF score ranges from 0 (no impact of heart failure) to 105 (severe impact of heart failure). Change in MNLWHF score was computed as the 12-month minus the baseline score.</description>
          <population>Subjects were required to respond to the baseline and 12-month follow-up visit to be included in the analysis.</population>
          <units>scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="177"/>
                <count group_id="O2" value="176"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline MNWHF score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49.7" spread="26.4"/>
                    <measurement group_id="O2" value="52.7" spread="28.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>12-month MNWHF score</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34.0" spread="25.6"/>
                    <measurement group_id="O2" value="37.2" spread="25.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change in MNWHF score from baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-15.7" spread="27.3"/>
                    <measurement group_id="O2" value="-15.6" spread="23.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: There is no difference in the change in MNLWHF score from baseline to 12-months between the Treatment Arm and Control Arm.
Alternative Hypothesis: There is a difference in the change in MNLWHF score from baseline to 12-months between the Treatment Arm and Control Arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.583</p_value>
            <method>Mixed Models Analysis</method>
            <method_desc>Response was change in MNLWHF score from baseline. Model adjusted for baseline MNLWHF score. Negative changes mean an improvement in MNLWHF score.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Characterize Arrhythmic Events</title>
        <description>The rate of spontaneous VT (ventricular tachycardia)/VF (ventricular fibrillation) episodes during the 12-month follow-up period in episodes per subject month was compared between the Treatment Arm and the Control Arm</description>
        <time_frame>12 months post implant</time_frame>
        <population>All 399 subjects successfully implanted with the Chronicle ICD were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Treatment Arm</title>
            <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
          <group group_id="O2">
            <title>Control Arm</title>
            <description>Physicians do not have access to device-based hemodynamic monitor information to guide patient management</description>
          </group>
        </group_list>
        <measure>
          <title>Characterize Arrhythmic Events</title>
          <description>The rate of spontaneous VT (ventricular tachycardia)/VF (ventricular fibrillation) episodes during the 12-month follow-up period in episodes per subject month was compared between the Treatment Arm and the Control Arm</description>
          <population>All 399 subjects successfully implanted with the Chronicle ICD were included in the analysis.</population>
          <units>VT/VF episodes per subject month</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="197"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.54" lower_limit="0.43" upper_limit="0.64"/>
                    <measurement group_id="O2" value="0.38" lower_limit="0.29" upper_limit="0.47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Null Hypothesis: Rate of VT/VF episodes during the 12-month randomized period is the same between the Treatment Arm and the Control Arm.
Alternative Hypothesis: Rate of VT/VF episodes during the 12-month randomized period is different between the Treatment Arm and the Control Arm.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.368</p_value>
            <p_value_desc>The P-value is from the Andersen-Gill model which adjusts for multiple VT/VF episodes per subject.</p_value_desc>
            <method>Andersen-Gill Model</method>
            <method_desc>Andersen-Gill model included a term for Treatment Arm. This model adjusts for multiple events per subject.</method_desc>
            <param_type>Hazard Ratio (HR)</param_type>
            <param_value>1.48</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.63</ci_lower_limit>
            <ci_upper_limit>3.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Time from enrollment through study closure</time_frame>
      <desc>The study collected all serious adverse events, all cardiovascular related adverse events, all adverse events related to the implanted system, and all adverse events related to the implant or system-modification procedure.</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment Arm</title>
          <description>Physicians have access to device-based hemodynamic monitor information to guide patient management</description>
        </group>
        <group group_id="E2">
          <title>Control Arm</title>
          <description>Physicians do not have access to device-based hemodynamic monitor information to guide patient management</description>
        </group>
        <group group_id="E3">
          <title>Enrolled, Not Randomized</title>
          <description>42 subjects were enrolled but exited the study prior to randomization</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="136" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="8" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>ANAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>FEBRILE NEUTROPENIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>IDIOPATHIC THROMBOCYTOPENIC PURPURA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>LEUKOCYTOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>THROMBOCYTOPENIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>ANGINA PECTORIS</sub_title>
                <counts group_id="E1" events="24" subjects_affected="14" subjects_at_risk="202"/>
                <counts group_id="E2" events="16" subjects_affected="12" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>ANGINA UNSTABLE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>ATRIAL FIBRILLATION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E2" events="13" subjects_affected="10" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>ATRIAL FLUTTER</sub_title>
                <counts group_id="E1" events="3" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>ATRIOVENTRICULAR BLOCK COMPLETE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>BRADYCARDIA</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>CARDIAC ARREST</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" events="138" subjects_affected="60" subjects_at_risk="202"/>
                <counts group_id="E2" events="166" subjects_affected="63" subjects_at_risk="198"/>
                <counts group_id="E3" events="7" subjects_affected="4" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>CARDIO-RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>CARDIOMYOPATHY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY DISEASE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>CORONARY ARTERY STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>ELECTROMECHANICAL DISSOCIATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>LOW CARDIAC OUTPUT SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>MYOCARDIAL INFARCTION</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PERICARDITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>SICK SINUS SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>SINUS ARRHYTHMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>SINUS BRADYCARDIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>TACHYCARDIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>TRICUSPID VALVE INCOMPETENCE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>VENTRICULAR ARRHYTHMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>VENTRICULAR FIBRILLATION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>VENTRICULAR TACHYCARDIA</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>HYPOTHYROIDISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PITUITARY-DEPENDENT CUSHING'S SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>ABDOMINAL ADHESIONS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>ABDOMINAL PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>COLITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>DIARRHOEA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>DIVERTICULAR PERFORATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>GASTRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>GASTROINTESTINAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>GASTROOESOPHAGEAL REFLUX DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>GINGIVAL BLEEDING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>HAEMORRHOIDAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>ILEUS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>IMPAIRED GASTRIC EMPTYING</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>LARGE INTESTINE PERFORATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PANCREATITIS ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PEPTIC ULCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PHARYNGOESOPHAGEAL DIVERTICULUM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>RETROPERITONEAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>SMALL INTESTINAL OBSTRUCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>UMBILICAL HERNIA, OBSTRUCTIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>VOMITING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>CATHETER RELATED COMPLICATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>CATHETER SITE HAEMATOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>DEATH</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>HERNIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>IMPLANT SITE HAEMATOMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>NON-CARDIAC CHEST PAIN</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PYREXIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>BILE DUCT STONE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>CHOLECYSTITIS ACUTE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>CHOLELITHIASIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PORTAL VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>TRANSPLANT REJECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>ABSCESS OF EYELID</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>BACTERAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>BACTERIAL DIARRHOEA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>BRONCHITIS</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>CELLULITIS</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>CENTRAL LINE INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>CLOSTRIDIAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>DEVICE RELATED INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>DIVERTICULITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>ENDOCARDITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>GANGRENE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>GASTROENTERITIS VIRAL</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>HERPES ZOSTER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>IMPLANT SITE INFECTION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>INCISION SITE INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>INFLUENZA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>LOCALISED INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>MENINGITIS ASEPTIC</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>OSTEOMYELITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PERIRECTAL ABSCESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PNEUMONIA</sub_title>
                <counts group_id="E1" events="11" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PNEUMONIA STAPHYLOCOCCAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PYELONEPHRITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>SEPSIS</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>SEPTIC SHOCK</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>TRACHEOBRONCHITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>UPPER RESPIRATORY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>URINARY TRACT INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>UROSEPSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>VIRAL INFECTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>WOUND INFECTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>ANKLE FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>DEFIBRILLATION THRESHOLD INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>DEVICE CONNECTION ISSUE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>DEVICE ELECTRICAL FINDING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>DEVICE FAILURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>DEVICE LEAD DAMAGE</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>DEVICE LEAD ISSUE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>DEVICE MALFUNCTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>DRUG TOXICITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>FAT EMBOLISM</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>GUN SHOT WOUND</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>HUMERUS FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>INAPPROPRIATE DEVICE PROGRAMMING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>INAPPROPRIATE DEVICE THERAPY</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>INCISION SITE HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>INCISION SITE PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>LEAD DISLODGEMENT</sub_title>
                <counts group_id="E1" events="7" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>POST PROCEDURAL SWELLING</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>ROAD TRAFFIC ACCIDENT</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>SEROMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>SUBDURAL HAEMATOMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>TIBIA FRACTURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>TWIDDLER'S SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>UPPER LIMB FRACTURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>ELECTROCARDIOGRAM QT PROLONGED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>INTERNATIONAL NORMALISED RATIO INCREASED</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>SYSTEMIC LUPUS ERYTHEMATOSUS DISEASE ACTIVITY INDEX INCREASED</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>TRANSPLANT EVALUATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>DEHYDRATION</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>DIABETES MELLITUS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>FAILURE TO THRIVE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>HYPERGLYCAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>HYPERKALAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>HYPOGLYCAEMIC SEIZURE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>HYPOKALAEMIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>HYPONATRAEMIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>HYPOVOLAEMIA</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="202"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>OBESITY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>ARTHRALGIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>ARTHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>BACK PAIN</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>COSTOCHONDRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>INTERVERTEBRAL DISC DEGENERATION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>MYALGIA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>NECK PAIN</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>NEUROPATHIC ARTHROPATHY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>OSTEOARTHRITIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>CARCINOID TUMOUR OF THE DUODENUM</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMANGIOMA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>COLON CANCER</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>NON-SMALL CELL LUNG CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PROSTATE CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>RENAL CANCER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>ALTERED MENTAL STATE LIKELY POSTICTAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY OCCLUSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>CAROTID ARTERY STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>CEREBRAL HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>CEREBROVASCULAR ACCIDENT</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>CONVULSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>DIZZINESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>HEMIPARESIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>HYPOAESTHESIA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>LACUNAR INFARCTION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>SPINAL CORD COMPRESSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>SUBARACHNOID HAEMORRHAGE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>SYNCOPE</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>SYNCOPE VASOVAGAL</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>TRANSIENT ISCHAEMIC ATTACK</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>TRIGEMINAL NEURALGIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>ALCOHOL WITHDRAWAL SYNDROME</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>DEPRESSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>DEVICE PSYCHOGENIC COMPLICATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>MENTAL DISORDER</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>MENTAL STATUS CHANGES</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>SUICIDAL IDEATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>HAEMATURIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>RENAL FAILURE ACUTE</sub_title>
                <counts group_id="E1" events="12" subjects_affected="10" subjects_at_risk="202"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="198"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>URINARY RETENTION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>ACUTE PULMONARY OEDEMA</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>ASTHMA</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>CHRONIC OBSTRUCTIVE PULMONARY DISEASE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>CHYLOTHORAX</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>COUGH</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PLEURAL EFFUSION</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PLEURISY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PNEUMONIA ASPIRATION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PNEUMOTHORAX</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PULMONARY EMBOLISM</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="202"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PULMONARY HYPERTENSION</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>RESPIRATORY ARREST</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>RESPIRATORY DISTRESS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>SLEEP APNOEA SYNDROME</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>SUBCUTANEOUS EMPHYSEMA</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>AORTIC BYPASS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>BILIARY DRAINAGE</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>CAROTID ENDARTERECTOMY</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>HEART TRANSPLANT</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>ILEOSTOMY CLOSURE</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>KNEE ARTHROPLASTY</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>MITRAL VALVE REPLACEMENT</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>RADIOACTIVE IODINE THERAPY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>THYROIDECTOMY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>VERTEBROPLASTY</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>ARTERIAL STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>DEEP VEIN THROMBOSIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>FEMORAL ARTERIAL STENOSIS</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>HYPOTENSION</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="202"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="198"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>ISCHAEMIA</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>PERIPHERAL VASCULAR DISORDER</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="202"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>THROMBOPHLEBITIS</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="202"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>THROMBOSIS</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="202"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
              <event>
                <sub_title>VENOUS OCCLUSION</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="202"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="202"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="198"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>CARDIAC FAILURE</sub_title>
                <counts group_id="E1" events="45" subjects_affected="24" subjects_at_risk="202"/>
                <counts group_id="E2" events="31" subjects_affected="25" subjects_at_risk="198"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="42"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Generally, contracts allow investigators to publish study results per the protocol and publication plan. Medtronic reviews publications to determine if confidential information (&quot;CI&quot;) is included. Any such CI is deleted before publication. Medtronic may not censor/interfere with the publication. Investigators may publish single-site publications after a decision by Medtronic that no multi-site study publication will be done or 12 months after the study is closed, whichever is earlier.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study was terminated early after 400 of an estimated 1300 subjects required were randomized. The study was terminated due to a pressure lead integrity issue based on analysis of pressure leads from other clinical trials.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>REDUCEhf Clinical Research Specialist</name_or_title>
      <organization>Medtronic CRDM</organization>
      <phone>1-800-328-2518 ext 62736</phone>
      <email>medtronicCRMtrials@medtronic.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

